Abbott Laboratories (ABT) said it has received U.S. Food and Drug Administration (FDA) approval for its cholesterol treatment Simcor.
Simcor has been approved for use to lower levels of elevated total cholesterol, LDL "bad" cholesterol and triglycerides, and to raise HDL "good" cholesterol in patients with complex lipid disease when treatment with simvastatin or Niaspan monotherapies are not considered adequate, the Illinois-based pharma company said.
The stock is up a point to $56.50 premarket. It has tried twice to break out about $60, but has failed. That is the level where I would put a buy order.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment